Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Enanta Pharmaceutica 500 ARSENAL STREET WATERTOWN MA 02472 USA

www.enanta.com Employees: 145 P: 617-607-0800 F: 617-607-0530

Description:

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 197,905
Enterprise Value, $K 113,935
Shares Outstanding, K 21,189
Annual Sales, $ 79,200 K
Annual Net Income, $ -133,820 K
Last Quarter Sales, $ 17,970 K
Last Quarter Net Income, $ -22,660 K
EBIT, $ -122,880 K
EBITDA, $ -123,360 K
60-Month Beta 0.56
% of Insider Shareholders 13.64%
% of Institutional Shareholders 94.99%
Float, K 18,299
% Float 86.36%
Short Volume Ratio 0.59

Growth:

1-Year Return -9.36%
3-Year Return -89.10%
5-Year Return -85.94%
5-Year Revenue Growth -61.67%
5-Year Earnings Growth -283.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.07 on 08/05/24
Next Earnings Date 11/25/24 [--]
Earnings Per Share ttm -5.45
EPS Growth vs. Prev Qtr 27.21%
EPS Growth vs. Prev Year 42.47%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ENTA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -63.75%
Return-on-Assets % -27.09%
Profit Margin % -168.96%
Debt/Equity 0.00
Price/Sales 2.64
Price/Cash Flow N/A
Price/Book 1.32
Book Value/Share 7.03
Interest Coverage -24.44
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar